GT Biopharma Inc GTBP 深 滬
等待開盤 11-26 09:30:00 美东时间
0.7476
-0.014
-1.79%
華盛通- 最 高0.7865
- 今 開0.77
- 成交量 52.14万股
- 最 低 0.74
- 昨 收 0.7612
- 總市值 795.15万
- 52周最高 4.10
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.54
- 委 比 91.23%
- 總股本 1063.61万
- 歷史最高 591.99
- 量 比 0.65
- 振 幅 6.11%
- 歷史最低 0.54
- 每 手 1
- 風險率 0.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
Shares of Quantum Computing Inc. (NASDAQ:QUBT) rose sharply in pre-market tradi...
11-17 17:42
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GT Biopharma announced updates on its Phase 1 trial for GTB-3650, targeting relapsed/refractory CD33+ hematologic malignancies, with enrollment ongoing and the next update expected in Q1 2026. The IND submission for GTB-5550, targeting B7H3+ solid tumors, is anticipated in late December 2025 or January 2026. The company reported a cash position of $2.6 million as of September 30, 2025, sufficient to fund operations into Q1 2026. R&D expenses decr...
11-14 14:00
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvard scientists recently created...
10-17 21:50
Precision Oncology Approaches Drive $312B Market Transformation
USA News Group News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, Oct. 17, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development accelerates ...
10-17 21:00
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
USA News Group News Commentary – Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development is acc...
10-15 21:11
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares rose 113.4% to $3.99 during T...
10-09 20:07
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why som...
10-08 22:58
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
GT Biopharma announced that enrollment in the Phase 1 trial for GTB-3650 is progressing well, with Cohort 3 patients initiating treatment without dose-limiting toxicities. The first Cohort 3 patient showed immune activation consistent with previous lower-dose cohorts. Cohort 4 dosing is planned by year-end 2025, with potential for up to 7 cohorts. Further updates are expected in Q1 2026.
10-08 13:00
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Major pharmaceutical companies presenting at...
10-07 20:00
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, announced that its CEO, Michael Breen, will participate in the Centurion One Capital 3rd Annual Bahamas Summit on October 28-29, 2025, in Nassau, Bahamas. The company will host one-on-one meetings during the conference. GT Biopharma focuses on developing immuno-oncology therapies using its proprietary TriKE® NK cell engager platform, licensed from the University of Minne...
10-06 13:00
